Treatment Outcomes of Mycobacterium avium Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol
Open Forum Infectious Diseases · 31.05.2025 · 12 (6)
DOI: 10.1093/ofid/ofaf292 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.05.2025. Verfasst von Yunjoo Im und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University Coll…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Patient-Centered Clinical Research Coordinating Center, Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Background
Limited data exist on the treatment outcomes of a 2-drug daily regimen of macrolide and ethambutol in patients with Mycobacterium avium complex pulmonary disease (MAC-PD).
Methods
An outcome analysis was performed on 108 patients with MAC-PD who underwent at least 12 months of treatment with macrolides and ethambutol. Microbiological responses, antibiotic resistance rates, and recurrence rates linked to the regimen were analyzed.
Results
The median overall treatment duration for 108 patients was 13.2 months (interquartile range 12.1–14.6 months). A total of 72 (67%) patients achieved culture conversion and microbiological cure, with a median time to culture conversion of 1.7 months (interquartile range 1.2–4.0 months). A clinical cure was observed in 11 patients; thus, 83 (77%) patients demonstrated a favorable overall response. In the multivariate analysis models adjusted for important clinical variables, no clinical factors were significantly associated with culture conversion. Among patients who failed to achieve culture conversion, macrolide resistance developed in 2 of 18 patients (11%) who had both pre- and posttreatment isolates available. In 2 other patients who failed culture conversion, the minimum inhibitory concentration for ethambutol in the posttreatment isolates increased to ≥8 μg/mL, which was considered resistant. Of the 72 patients who achieved a microbiological cure, 16 (22%) experienced recurrence during follow-up.
Conclusions
The 2-drug daily regimen of macrolides and ethambutol showed moderate efficacy in treating MAC-PD when used for >12 months. However, macrolide resistance occurred in some refractory cases, and recurrence was noted even after successful treatment, highlighting the need for close follow-up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, South Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
ORCID-Profile: Byung Woo Jhun
Förderung
- Patient-Centered Clinical Research Coordinating Center
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Im, Y., Choe, J., Kim, D. H., Kim, S. Y., & Jhun, B. W. (2025). Treatment Outcomes of Mycobacterium avium Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol. Open Forum Infectious Diseases, 12(6). https://doi.org/10.1093/ofid/ofaf292
Vancouver
Im Y, Choe J, Kim DH, Kim SY, Jhun BW. Treatment Outcomes of Mycobacterium avium Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol. Open Forum Infectious Diseases. 2025;12(6). doi:10.1093/ofid/ofaf292
BibTeX
@article{Im2025,
author = {Im, Yunjoo and Choe, Junsu and Kim, Dae Hun and Kim, Su-Young and Jhun, Byung Woo},
title = {Treatment Outcomes of Mycobacterium avium Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {6},
doi = {10.1093/ofid/ofaf292}
}
EUVIMED